Taking Herpes Pills Daily? What They Actually Do (and Don't)

Published: November 2025 | Last updated: May 2026

Daily antivirals for genital herpes are among the most asked-about prescriptions in sexual health. People want a clear answer to a few specific questions: what does the pill do, does it stop outbreaks completely, does it make someone non-contagious to partners, and is it safe to take year after year?

The honest answer is layered. Suppressive therapy reliably reduces both outbreak frequency and the risk of passing herpes to a partner. It does not eliminate either. Knowing where the line falls matters, because expecting a cure leaves room for confusion and self-blame when reality does not match the hope. Many people start daily valacyclovir expecting to never have a flare again, then panic when a familiar tingle returns four months in.

This guide walks through what daily valacyclovir, acyclovir, and famciclovir do in practice, how they compare, when they make sense, and what trade-offs come with long-term use. The information draws on current CDC STI Treatment Guidelines, WHO guidance, and the published transmission and safety studies those guidelines are built on.

Who suppressive therapy is really for

Suppressive therapy is not only for people with constant outbreaks. The CDC STI Treatment Guidelines describe it as a reasonable option for anyone with recurrent genital herpes who wants to reduce flare frequency, for people in serodiscordant relationships where transmission to a partner is a concern, and for those whose recurrences cause significant distress or disruption to daily life.

The threshold many providers use as a starting point is roughly six or more outbreaks per year, but the cutoff is soft. A person with two or three severe outbreaks per year may still benefit if those flares are deeply disruptive. Someone with eight mild outbreaks may decide they would rather treat each one episodically than commit to a daily pill. The decision is not driven by a single number; it is driven by the lived impact of the virus on the person sitting in the exam room.

The pattern of triggers also matters. When outbreaks track predictably with menstrual cycles, periods of intense stress, illness, or sleep loss, a daily preventative often makes more sense than waiting for symptoms because the trigger is recurring and unavoidable. Episodic treatment, taken only when symptoms appear, can fall short for this group because the prodrome window is short and life sometimes does not allow a same-day pharmacy run.

Suppression also serves a role that is sometimes overlooked: it lowers the mental load of living with the diagnosis. Knowing that the daily pill is doing background work can shift attention away from constant body monitoring. Whether that emotional benefit is worth the routine is a personal call, not a clinical one, and a good prescribing visit will discuss it openly.

What daily antivirals actually do

Valacyclovir, acyclovir, and famciclovir are nucleoside analogs. They resemble the building blocks the herpes virus uses to copy itself, so the virus incorporates them and then cannot complete replication. The result is fewer infectious viral particles circulating in skin and mucosal tissue, which translates into fewer days of viral shedding and fewer symptomatic outbreaks.

These drugs do not clear the latent reservoir. Herpes simplex virus hides in sensory nerve ganglia, and no current antiviral reaches it there. That is why every credible source, including the CDC and WHO, frames suppressive therapy as containment rather than eradication. The virus is still present in your body during therapy; the medication keeps it quiet most of the time.

How quiet depends on the person. Randomized trials consistently show that daily valacyclovir or acyclovir reduces clinically apparent outbreaks by 70 to 80 percent in people with frequent recurrences. Asymptomatic shedding (viral activity in the skin without visible symptoms) drops too, though not to zero. Research from the University of Washington virology group has shown that even with daily valacyclovir, low-level shedding still occurs on a small fraction of days, mostly without producing visible lesions.

The practical implication is that the pill changes the math of daily life with herpes but does not flip a switch. A person on consistent suppression has fewer outbreak days, fewer shedding days, and a lower per-act transmission risk to a partner. They do not have zero of any of these.

Why outbreaks can still happen on suppression

Roughly a quarter to a third of people on consistent daily therapy still experience at least one outbreak per year. The numbers in published trials usually land between 70 and 80 percent reduction in recurrences, which means a meaningful minority continue to have breakthrough flares even when taking the medication exactly as prescribed.

Several factors influence whether a flare happens despite the medication. Adherence is the largest one. Missing doses, especially several in a row, lets viral replication catch up. Even with perfect adherence, other forces still play a role. Physical stress (lack of sleep, intense exercise, a concurrent illness) can trigger reactivation. So can hormonal shifts around menstruation. Friction from sex, tight clothing, or hair removal can locally irritate the area and prompt the nerve to release virus.

A breakthrough does not mean the medication has failed. Compared to outbreaks without therapy, breakthroughs on suppression are usually milder, heal faster, and involve fewer days of shedding. Providers generally evaluate whether suppression is working at the six- to twelve-month mark, not after a single breakthrough, because outbreak frequency is the long-term metric.

If breakthroughs are frequent or severe despite consistent dosing, the dose can sometimes be increased (for example, 500 mg of valacyclovir daily moved up to 1 g daily), or the drug switched. Persistent severe recurrences also warrant checking for other contributing infections, since HSV reactivation can be driven by changes in immune status.

How long until the meds start working

The antiviral effect starts within hours. Once valacyclovir or acyclovir is in your bloodstream, replication of any actively dividing virus slows, which is why these same drugs (at higher doses) are also used episodically to shorten an active outbreak.

The broader suppression effect, meaning fewer flares and less asymptomatic shedding, builds gradually over weeks. The first month is when many people report noticing fewer prodrome tingles and faster healing of any minor episodes. By two to three months, the baseline shedding rate is usually meaningfully lower. Most providers recommend assessing the response at six to twelve months before deciding whether to continue, change dose, or step down to episodic therapy.

If you are starting suppression specifically to protect a partner, providers commonly recommend pairing the daily medication with condoms during the first several weeks while shedding rates are still settling. This is not because the drug is failing during that period; it is because the transmission-risk reduction documented in trials reflects months of consistent dosing, not a few days.

Suppression and partner transmission risk

The most often-cited study on transmission was published in the New England Journal of Medicine in 2004 by Corey and colleagues. It enrolled almost 1,500 monogamous heterosexual couples in which one partner had genital HSV-2 and the other did not. The HSV-2 positive partner took 500 milligrams of valacyclovir daily for eight months. Symptomatic HSV-2 acquisition in the previously uninfected partner dropped by 75 percent compared with placebo. Overall HSV-2 acquisition (symptomatic plus asymptomatic seroconversion) dropped by 48 percent.

That 48 percent figure is what clinicians usually quote when discussing suppression for transmission reduction. It is also worth saying out loud what the study did and did not measure. The trial was on heterosexual couples, the index partner was usually the woman, and the result has not been replicated in every demographic. The CDC nevertheless endorses daily valacyclovir as a transmission-reduction tool, and consistent condom use adds independent protection on top, with combined estimates suggesting an additional 30 to 50 percent reduction.

What suppression does not do is bring transmission risk to zero. The virus still sheds occasionally, sometimes on days with no visible symptom and no warning. Disclosure to partners therefore remains the standard of care, regardless of whether someone is on daily medication. Most clinicians who counsel couples on this point describe suppression and condoms as a combined strategy, not a substitute for the disclosure conversation.

A practical note on testing partners: before relying on suppression to protect a partner, the partner's HSV-1 and HSV-2 status is genuinely useful information. Some partners already carry HSV-2 antibodies from a previous exposure they never knew about, which changes the conversation entirely. This article links to at-home rapid tests sold on this site, which is one option for partner screening alongside clinic-based testing.

Suppressive therapy reduces the frequency of genital herpes recurrences by 70 to 80 percent in patients who have frequent recurrences. Many people benefit from suppressive therapy, even those with less frequent recurrences.

Combined HSV-1 and HSV-2 Home Antibody Test

Genital & Oral Herpes Rapid Self-Test Kit

$118.00

Rapid fingerstick blood antibody test screening for HSV-1 and HSV-2 in about 15 minutes. Useful for confirming exposure or checking a partner's status. A blood antibody test cannot diagnose an active lesion (clinic swab/PCR is the right tool there), but it does answer the seroconversion question at home, privately.

See the herpes test kit

Daily versus episodic therapy

Suppressive (daily) and episodic (as-needed) therapy are both reasonable strategies in CDC and WHO guidance. The choice depends on outbreak frequency, partner status, and personal preference.

Episodic therapy means keeping antivirals on hand and starting them at the first sign of prodrome (tingling, itching, burning, or a small spot of irritation in the usual location). Started within 24 hours of prodrome, episodic dosing can shorten an outbreak by one to two days and reduce its severity. It does little for asymptomatic shedding between outbreaks, so it is not a transmission-reduction strategy.

Daily suppression is typically chosen by people who have six or more outbreaks per year, who are in a relationship with an uninfected partner, who experience significant emotional impact from recurrences, or whose outbreaks tend to be severe enough to disrupt work or sleep. Some people switch between the two strategies over time. A common pattern is daily suppression during a new relationship or pregnancy, then a step-down to episodic once life is steadier and outbreak frequency has dropped on its own.

Considerations a provider commonly weighs:

• Frequency: fewer than four outbreaks per year often does not justify daily therapy
• Severity: severe or prodrome-heavy outbreaks favor daily prevention
• Transmission concern: an uninfected partner usually tips the balance toward daily
• Pill-taking tolerance: some people simply do not want a daily routine, and that preference is legitimate
• Cost and insurance coverage of long-term generic versus brand-name medication

A practical hybrid some clinicians suggest: episodic by default, with a planned switch to daily suppression around predictable trigger periods (new partner, exam season, travel, third trimester of pregnancy).

Essential 6-Test STI Home Screening Panel

Essential 6-in-1 STD At-Home Rapid Test Kit

$354.00

Rapid lateral-flow screening for six common STIs in one kit, combining fingerstick blood and self-collected swab samples. A useful baseline panel before starting a new relationship or before beginning suppression therapy, so that both partners enter the conversation knowing their full status.

See the 6-in-1 kit

Stopping suppressive therapy

There is no withdrawal effect from stopping antivirals. The drugs leave the body within a couple of days, and the immune system goes back to managing the virus on its own.

What stopping reveals is your natural outbreak pattern in the current state of your life. Outbreak frequency often declines over the first few years after an initial herpes infection, regardless of whether someone has been on suppression. Some people who stop after a year or two of daily therapy find their underlying rate has dropped to one or two flares per year, which is comfortably in episodic territory. Others find the previous frequency returns within a few months.

If you are stopping suppression while still in a partnered relationship where transmission was the original concern, talk to your provider first. Common strategies include staying on daily therapy through high-risk life periods (a new relationship, pregnancy, an immunosuppressive treatment), tapering during a stable low-stress stretch, or coordinating the change with the partner getting an HSV-2 antibody test of their own.

One thing not to do: stop because of a single side-effect day. Mild nausea, headache, or fatigue that appears in week one often resolves by week three. Stopping inside the first month makes it hard to tell whether the medication was going to work, so it is usually worth pushing through the initial adjustment period before drawing conclusions.

Long-term safety of daily antivirals

Valacyclovir and acyclovir have been studied at suppressive doses for more than a decade in some cohorts, and the safety record in otherwise healthy adults is reassuring. The main side effects in trials and in routine practice are mild and uncommon: occasional headache, nausea, abdominal discomfort, or fatigue. Most resolve within the first few weeks or with a small dose adjustment.

Kidney handling is the one area providers watch. Both drugs are cleared by the kidneys, and people with impaired renal function may need a reduced dose. Severe renal complications are rare but described, mostly in people with pre-existing kidney disease or those taking other nephrotoxic medications. Bloodwork is not routinely required for healthy adults on standard suppressive doses, but providers may order periodic creatinine checks for people with risk factors or for those staying on therapy for many years.

Drug interactions are limited but worth flagging at the prescribing visit. Probenecid and cimetidine can raise valacyclovir levels. Other nephrotoxic drugs (some antibiotics, certain chemotherapy agents) deserve a closer look when combined with daily antiviral suppression.

Pharmacy cost and access are more often the practical limit on long-term use. Generic valacyclovir and acyclovir are available in most countries, and many insurance plans cover them. Cash prices for generic acyclovir 400 mg twice daily are often the cheapest long-term option. Brand-name Valtrex can be substantially more expensive, with no clinical advantage over the generic for most patients.

Suppression during pregnancy

Suppressive therapy plays a specific, evidence-supported role in pregnancy. The American College of Obstetricians and Gynecologists and the CDC both recommend daily suppressive antiviral therapy starting around 36 weeks of gestation for people with a history of genital herpes. The goal is to reduce the chance of viral shedding at the time of delivery, which lowers the risk of neonatal herpes (a rare but serious infection that can occur when a newborn passes through a birth canal with active virus).

Valacyclovir and acyclovir are both considered acceptable in pregnancy. Registry data covering large numbers of exposed pregnancies have not shown an increased risk of birth defects with first-trimester exposure, though most pregnancy-specific recommendations focus on the third trimester. Anyone with a history of genital herpes should mention it early in prenatal care, because the third-trimester suppression plan and the cesarean-delivery decision (made if there is an active outbreak or prodrome at the time of labor) are decided together with the OB.

Pre-conception, partner testing matters too. A pregnant person who acquires herpes for the first time in the third trimester has the highest risk of passing the virus to the newborn, because maternal antibody protection has not had time to develop and cross the placenta. This is one situation where knowing both partners' HSV-1 and HSV-2 status before conception meaningfully changes the management plan. If only one partner is positive, suppression in the positive partner plus condom use through the pregnancy reduces the chance of a new maternal infection.

The emotional weight of a daily pill

Beyond the pharmacology, taking a pill every morning for an incurable virus carries a psychological tone of its own. For some people the routine is grounding. The daily action is evidence of control, of doing something concrete to protect themselves and a partner. For others, the morning pill is a daily reminder of a diagnosis they did not choose, and the routine itself adds to the mental load.

Both responses are normal. Providers familiar with herpes management often raise this during follow-up visits because the medication's value extends past outbreak frequency. If the daily pill is reducing anxiety, it is doing useful work even on days the virus would have been quiet anyway. If the pill is increasing daily distress without a strong transmission or frequency reason behind it, episodic therapy may serve the same medical need with less mental friction.

Counseling and peer-support resources help with the parts of living with herpes that medication cannot reach: disclosure conversations, stigma, the spiral of anxiety around a partner's reaction. The medical question of which antiviral and at what dose is, in many cases, easier to answer than the broader question of what role the diagnosis takes up in your life. Both questions matter, and they often need different kinds of support.

If you are weighing whether daily suppression is the right step, the most useful conversation is with a provider who knows your outbreak history, your relationship situation, and your priorities. The pharmacology is well-mapped. The personal calculus around it is the part that benefits from a real discussion.

1. U.S. Centers for Disease Control and Prevention. STI Treatment Guidelines: Genital Herpes (suppressive and episodic therapy regimens, pregnancy guidance).
2. U.S. Centers for Disease Control and Prevention. About Genital Herpes (overview of HSV-1, HSV-2, shedding, transmission).
3. World Health Organization. Herpes Simplex Virus fact sheet (global epidemiology and treatment overview).
4. National Health Service (UK). Genital Herpes: treatment and self-care guidance.
5. Mayo Clinic. Genital Herpes: symptoms, causes, and management.
6. Corey L, Wald A, Patel R, et al. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. New England Journal of Medicine. 2004;350:11-20. (The reference trial for the ~48% transmission-reduction figure quoted throughout.)
7. American College of Obstetricians and Gynecologists. Genital Herpes: patient FAQ and clinical guidance (third-trimester suppression and delivery planning).

Maya Chen

Maya writes plain-English explainers on STI screening, prevention, and at-home testing. Background in epidemiology research at a state public-health department; articles synthesize CDC and peer-reviewed guidance, not personal clinical advice.